<div id="readability-page-1"><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Sino Biopharmaceutical ( (HK:1177) ) has issued an announcement. Sino Biopharmaceutical’s wholly owned unit LaNova Medicines has showcased new preclinical data on two antibody-drug conjugates, LM-364 and LM-338, at the American Association for Cancer Research Annual Meeting 2026, underscoring its push into next-generation oncology biologics. The programs target solid tumors with technologies aimed at improving tumor selectivity and safety profiles, reinforcing the group’s positioning in high-value cancer therapeutics. LM-364, a Nectin-4 tumor microenvironment-activated ADC, demonstrated strong antitumor activity across multiple patient-derived xenograft models and a favorable safety profile in animal studies, and has already progressed to an IND filing with the U.S. FDA ahead of a planned first-in-human trial in 2026. LM-338, designed as a potential first-in-class ADC against the tumor-specific STn glycan antigen, showed high target specificity and efficient internalization, signaling future pipeline expansion in solid tumor indications if later-stage data confirm these preclinical results. The most recent analyst rating on (HK:1177) stock is a Buy with a HK$8.70 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page. More about Sino Biopharmaceutical Sino Biopharmaceutical Limited is a China-focused pharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative therapies, with a strong emphasis on oncology. Through subsidiaries such as LaNova Medicines, it develops advanced antibody-drug conjugates and other targeted treatments for solid tumors and other cancers. Average Trading Volume: 69,721,589 Technical Sentiment Signal: Buy Current Market Cap: HK$110.3B Learn more about 1177 stock on TipRanks’ Stock Analysis page.</div>

01177

560600

516930

Sino Biopharmaceutical's unit LaNova Medicines presented promising preclinical data on two antibody-drug conjugates, LM-364 and LM-338, at the AACR Annual Meeting 2026. These ADCs target solid tumors, with LM-364 showing strong antitumor activity and a favorable safety profile, progressing towards an IND filing with the U.S. FDA. LM-338 demonstrated high target specificity, indicating potential for future pipeline expansion. Analysts rate Sino Biopharmaceutical (HK:1177) stock as a Buy with a price target of HK$8.70, reflecting confidence in its oncology-focused innovations.

Tip Ranks

SBP GROUP

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Guotai SSE STAR Brand Name Drug ETF

Huaan Hang Seng Biotech ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

E Fund Hang Seng SCHK Innovative Drug ETF

First Trust NYSE Arca Biotech Index Fd

China Universal 800 Health Care ETF

Sino Biopharm Unit LaNova Unveils Promising ADC Data at AACR 2026